New developments in the management of hepatitis C virus infection: focus on boceprevir

New developments in the management of hepatitis C virus infection: focus on boceprevir

Marina Berenguer,1–3 F Xavier López-Labrador4–61Hepatology-Liver Transplantation Unit, Digestive Medicine Service, Hospital Universitari La Fe, Valencia, Spain; 2Department of Medicine, University of Valencia, Valencia, Spain; 3CIBERehd, Instituto de Salud...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Berenguer M, López-Labrador FX
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2012
Materias:
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/76dc9770a0764ccb96417a8c9b27b59f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:76dc9770a0764ccb96417a8c9b27b59f
record_format dspace
spelling oai:doaj.org-article:76dc9770a0764ccb96417a8c9b27b59f2021-12-02T01:09:00ZNew developments in the management of hepatitis C virus infection: focus on boceprevir1177-54751177-5491https://doaj.org/article/76dc9770a0764ccb96417a8c9b27b59f2012-08-01T00:00:00Zhttp://www.dovepress.com/new-developments-in-the-management-of-hepatitis-c-virus-infection-focu-a10607https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Marina Berenguer,1–3 F Xavier López-Labrador4–61Hepatology-Liver Transplantation Unit, Digestive Medicine Service, Hospital Universitari La Fe, Valencia, Spain; 2Department of Medicine, University of Valencia, Valencia, Spain; 3CIBERehd, Instituto de Salud Carlos III, Madrid, Spain; 4CSISP, Center for Public Health Research, Public Health Department, Generalitat Valenciana, Valencia, Spain; 5Microbiology Department and Institut Cavanilles, University of Valencia, Valencia, Spain; 6CIBEResp, Instituto de Salud Carlos III, Madrid, SpainAbstract: Chronic hepatitis C virus infection is an important public health problem, and the standard treatment (combination of pegylated interferon-α and ribavirin) has an effectiveness rate of only 40%–50%. Novel virus-specific drugs have recently been designed, and multiple compounds are under development. The approval for the clinical use of direct-acting antivirals in 2011 (boceprevir [BOC] and telaprevir, viral NS3 protease inhibitors) has increased recovery rates by up to 70%. Therefore, a highly effective treatment has been envisioned for the first time. This paper focuses on BOC and the implementation of new BOC-based treatment regimes.Keywords: HCV, antiviral therapy, protease inhibitors, viral resistanceBerenguer MLópez-Labrador FXDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2012, Iss default, Pp 249-256 (2012)
institution DOAJ
collection DOAJ
language EN
topic Medicine (General)
R5-920
spellingShingle Medicine (General)
R5-920
Berenguer M
López-Labrador FX
New developments in the management of hepatitis C virus infection: focus on boceprevir
description Marina Berenguer,1–3 F Xavier López-Labrador4–61Hepatology-Liver Transplantation Unit, Digestive Medicine Service, Hospital Universitari La Fe, Valencia, Spain; 2Department of Medicine, University of Valencia, Valencia, Spain; 3CIBERehd, Instituto de Salud Carlos III, Madrid, Spain; 4CSISP, Center for Public Health Research, Public Health Department, Generalitat Valenciana, Valencia, Spain; 5Microbiology Department and Institut Cavanilles, University of Valencia, Valencia, Spain; 6CIBEResp, Instituto de Salud Carlos III, Madrid, SpainAbstract: Chronic hepatitis C virus infection is an important public health problem, and the standard treatment (combination of pegylated interferon-α and ribavirin) has an effectiveness rate of only 40%–50%. Novel virus-specific drugs have recently been designed, and multiple compounds are under development. The approval for the clinical use of direct-acting antivirals in 2011 (boceprevir [BOC] and telaprevir, viral NS3 protease inhibitors) has increased recovery rates by up to 70%. Therefore, a highly effective treatment has been envisioned for the first time. This paper focuses on BOC and the implementation of new BOC-based treatment regimes.Keywords: HCV, antiviral therapy, protease inhibitors, viral resistance
format article
author Berenguer M
López-Labrador FX
author_facet Berenguer M
López-Labrador FX
author_sort Berenguer M
title New developments in the management of hepatitis C virus infection: focus on boceprevir
title_short New developments in the management of hepatitis C virus infection: focus on boceprevir
title_full New developments in the management of hepatitis C virus infection: focus on boceprevir
title_fullStr New developments in the management of hepatitis C virus infection: focus on boceprevir
title_full_unstemmed New developments in the management of hepatitis C virus infection: focus on boceprevir
title_sort new developments in the management of hepatitis c virus infection: focus on boceprevir
publisher Dove Medical Press
publishDate 2012
url https://doaj.org/article/76dc9770a0764ccb96417a8c9b27b59f
work_keys_str_mv AT berenguerm newdevelopmentsinthemanagementofhepatitiscvirusinfectionfocusonboceprevir
AT lampoacutepezlabradorfx newdevelopmentsinthemanagementofhepatitiscvirusinfectionfocusonboceprevir
_version_ 1718403265199079424

Ejemplares similares